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Abstract
Omar S. Al-Odat
SELECTIVE SMALL MOLECULE TARGETING OF MCL-1 IN MULTIPLE
MYELOMA
2020-2021
Subash Jonnalagadda, Ph.D.
Manoj K. Pandey, Ph.D.
Master of Science in Pharmaceutical Sciences
Multiple Myeloma (MM) is a deadly blood malignancy, characterized by the
uncontrolled proliferation of aberrantly differentiated plasma cells. MM is challenging to
diagnose and treat, accounting for approximately 12% of hematologic malignancies. The
overexpression of anti-apoptotic group of Bcl-2 family proteins, particularly Myeloid cell
leukemia 1 (Mcl-1), play a critical role in the pathogenesis of MM. The overexpression of
Mcl-1 is associated with drug resistance and overall poor prognosis. Thus, inhibition of
the Mcl-1 protein is an attractive therapeutic strategy against myeloma cells. Over the last
decade, the development of selective Mcl-1 inhibitors has seen remarkable advancement.
In this project, we investigated the effect of the novel Mcl-1 inhibiting agent KS18 on
MM cells. We demonstrated the molecules in vitro efficacy as well superior potency
towards MM. However, Mcl-1 inhibition by KS18 was associated with a significant
reduction of MM cell viability. Moreover, we observed that KS18 was able to induce
apoptosis in MM cells in a caspase-dependent manner. Our results propose that targeting
Mcl-1 by KS18 may represent a new viable strategy for MM treatment. Furthermore, the
present study uncovers the mechanism of action of KS18 and provides the foundation for
in vivo assessment of this novel molecule.

v

Table of Contents
Abstract ............................................................................................................................... v
List of Figures .................................................................................................................. viii
List of Tables ..................................................................................................................... ix
Chapter 1: Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma....................... 1
Introduction ................................................................................................................... 1
Mcl-1 Protein as a Potential Target for Multiple Myeloma (MM) ............................... 6
Regulation of Mcl-1 Protein ....................................................................................... 10
Development of Selective Mcl-1 Inhibitors ................................................................ 15
Indole-2-Carboxylic Acids Analog (A-1210477) ................................................. 21
Marinopyrrole A (Maritoclax) .............................................................................. 22
Mcl-1 Inhibitor Molecule 1 (MIM1)..................................................................... 22
UMI-77 ................................................................................................................. 23
S63845 .................................................................................................................. 23
AMG-176 .............................................................................................................. 25
AZD5991 .............................................................................................................. 26
VU661013 ............................................................................................................. 27
Chapter 2: Methods and Materials .................................................................................... 29
Antibodies and Compounds ........................................................................................ 29
Cell Culture ................................................................................................................. 29
Cell Viability Assay .................................................................................................... 30

vi

Table of Contents (Continued)
Western Blot Analysis ................................................................................................ 31
Chapter 3: Results and Discussion .................................................................................... 34
KS18 and Mcl-1 Anti-Apoptotic Protein .................................................................... 34
KS18 Molecule Reduces Cell Viability of MM ......................................................... 34
Anti-Apoptotic Proteins Expression in MM Cells ...................................................... 34
KS18 Selectively Inhibits Mcl-1 Expression in U266 Cells ....................................... 37
KS18 Induces Apoptosis in Caspase-Dependent Manner .......................................... 39
Chapter 4: Conclusion and Future Direction .................................................................... 41
References ......................................................................................................................... 43

vii

List of Figures
Figure

Page

Figure 1. Multiple Myeloma (MM) .................................................................................... 2
Figure 2. The Programmed Cell Death Via Intrinsic and Extrinsic Pathways in Normal
Mammalian Cells.. .............................................................................................................. 8
Figure 3. Bone Marrow Microenvironment (BMM) in MM ............................................ 11
Figure 4. Chemical Structures of Selective Mcl-1 Inhibitors ........................................... 17
Figure 5. The Placement of Flasks in CO2 Incubator ....................................................... 30
Figure 6. MTT Assay Mechanism .................................................................................... 31
Figure 7. Chemical Structures of Pyoluteorin and KS18 .................................................. 34
Figure 8. Anti-Apoptotic Proteins Expression in MM Cell Lines .................................... 36
Figure 9. Effect of KS18 on Cell Vibillity of MM Cells .................................................. 37
Figure 10. Down Regulation of Mcl-1 by KS18 in U266 Cells ....................................... 38
Figure 11. Inhibition of Mcl-1 Induces Apoptosis in U266 Cells .................................... 40

viii

List of Tables
Table

Page

Table 1. Mechanism of Action and Side Effects of Common Therapy in MM ................. 4
Table 2. Direct Mcl-1 Inhibitors BH3 Mimetic and Semi BH3 Mimetic Agents............. 18

ix

Chapter 1
Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
Introduction
The plasma cells are a type of unique B cells that reside in the bone marrow
(BM) and secrete an antibody corresponding to the antigen. When these plasma cells
begin proliferating out of control, they can build up within the BM and form numerous
tumors (Figure 1). This type of neoplasms is called Multiple Myeloma (MM) and is
considered the second most common hematologic malignancy, accounting for around
12% of hematological malignancies [1]. MM is slightly more common among older men,
with a median age of 65 years, and it is rarely diagnosed in younger people [2-4].
Depending on the stage of the disease, symptoms of MM begin with abnormalities in the
bone and calcium homeostasis, low blood cell counts, renal insufficiency, and multiple
infections. Because the symptoms are so generalized, MM is a challenging disease to
diagnose. Furthermore, the protective role of the BM on the proliferating plasma cells
makes it even more challenging to treat.
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Figure 1
Multiple Myeloma (MM)

Note. MM is a type of blood cancer that initiates from the bone marrow (BM), arising
from the aberrant proliferation of plasma cells.

In the last several decades, the treatment options for MM have dramatically
improved. Unfortunately, the survival rate is marginal [5]. According to the American
Cancer Society 2021 estimation, approximately 34,920 new MM cases will be diagnosed
(19,320 men and 15,600 women), approximately 12,410 cancer deaths (6,840 men and
5,570 women) from MM alone in the United States [6]. Table 1 illustrates the common
drugs that have been used to treat MM patients. Most therapeutic approaches to date for
MM patients, especially in relapsed/refractory (R/R) cases have been based on combined
formulations of available therapies. In spite of the efficacy and diversity of therapeutic
2

approaches, drug resistance is a major challenge as MM continues to show high rates of
relapse and quickly acquired resistance to therapies [7]. There are several unanswered
questions regarding MM including: what are the causes of progression of MM from its
precursor state? Why MM patients instigate to relapse? How MM clones resistant to
drugs persist in the presence of effective therapies?
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Table 1
Mechanism of Action and Side Effects of Common Therapy in MM
Drug

Mechanism of Action

Side Effects

Ref.

Melphalan

Chemotherapy drug

Bone marrow damage and chemotherapy side effects.

[8]

Drowsiness, fatigue, constipation, and painful nerve damage as well

[9]

Thalidomide
(Thalomid).
Bortezomib
(Velcade)

Immunomodulating agent
Proteasome inhibitor

as severe birth defects when taken during pregnancy.
Vomiting, tiredness, diarrhea, constipation, decreased appetite, fever, [10]
lowered blood counts and nerve damage.
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Lenalidomide

Small molecule analogue

Drowsiness, fatigue, constipation, and painful nerve damage as well

[11-

(Revlimid)

of thalidomide

as severe birth defects when taken during pregnancy.

13]

Tiredness, nausea, vomiting, diarrhea, shortness of breath, fever and

[14]

Carfilzomib
(Kyprolis)

Proteasome inhibitor

low blood counts and occasionally more serious problems such as
pneumonia, heart problems, and kidney or liver failure.

Pomalidomide Small molecule analogue

Same thalidomide side effects with a less risk of nerve damage side

(Pomalyst)

of thalidomide

effect.

Panobinostat

Oral Histone deacetylase

Feeling tired, weakness, nausea, diarrhea vomiting, loss of appetite,

(Farydak)

(HDAC) inhibitor

fever, swelling in the arms or legs, and occasionally altered blood

[15]
[16]

Drug

Mechanism of Action

Side Effects

Ref.

cell counts and blood electrolytes. Rare cases of internal bleeding,
liver damage, and changes in heart rhythm which can sometimes be
life threatening.
Ixazomib
(Ninlaro)
Daratumumab
(Darzalex)

Oral Proteasome inhibitor
Intravenous monoclonal
antibody

Elotuzumab
5

(Empliciti)

Nausea, vomiting, diarrhea, constipation, swelling in the hands or

[17]

feet, back pain, lowered blood platelet count and nerve damage.
Coughing, wheezing, trouble breathing, throat tightness, runny nose,

[18]

nasal congestion, feeling dizzy or lightheaded, headache, rash,
nausea, fatigue, back pain, fever, and lower blood cell counts.
Chills, feeling dizzy or lightheaded, wheezing, trouble breathing,

Intravenous monoclonal

cough, tightness in the throat, runny nose, nasal congestion, upper

antibody

respiratory tract infections and pneumonia, rash, fatigue, loss of

[19]

appetite, diarrhea, constipation, fever, and nerve damage
Selinexor
(Xpovio)

Oral Nuclear export
inhibitor of XPO1

Diarrhea, nausea, vomiting, loss of appetite, weight loss, low blood
sodium levels susceptibility to infection, low platelet counts, and low
white blood cell counts,

[20]

Mcl-1 Protein as a Potential Target for Multiple Myeloma (MM)
Apoptosis is a vital procedure for regular development and maintaining tissue
homeostasis. Mammalian apoptosis occurs via one of two distinct pathways, either the
intrinsic or extrinsic pathways (Figure 2). Both the intrinsic and extrinsic pathways end
with the activation of a certain group of protease enzymes called Caspase proteins. The
intrinsic pathway entails mitochondrial outer membrane permeabilization (MOMP) that
regulated directly by interactions between B cell lymphoma 2 (Bcl-2) family proteins.
The Bcl-2 family proteins are critical regulators of apoptosis. The members of this family
proteins are divided into three groups according to function: anti-apoptotic proteins (Bcl2, Mcl-1, Bcl-xL, Bcl-W, and Bfl-1); pro-apoptotic BH3-only proteins (Noxa, Puma,
Bim, Bid, Bad, BMF, and Bik); and multi-domain pro-apoptotic proteins (Bax, Bak, and
Bok). Intrinsic pathways like cytokine deprivation or DNA damage promote
overexpression and activation of BH3-only proteins, which stimulate apoptosis in two
different ways. First, the BH3-only proteins behave as inhibitors of anti-apoptotic
proteins by competing for their binding with Bax and Bak proteins [21] (Figure 2). This
is accomplished via the amphipathic α-helix of the BH3 domain that contains four
hydrophobic residues (h1-h4) that bind four hydrophobic pockets (P1−P4) within the
anti-apoptotic proteins in their BH3 binding groove [22-24]. For example, Noxa
selectively inhibits Mcl-1 with high affinity binding thereby indirectly activating the
Bax/Bak pathway [25, 26]. Simultaneously, BH3-only proteins can also result in the
direct activation of multi-domain pro-apoptotic proteins Bax and Bak, which cause
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MOMP, leading to release of Cytochrome C and SMAC proteins into the cytosol
resulting in downstream Caspase activation and ultimately activation of apoptosis [27].
The extrinsic pathway is promoted by death receptors activation. This leads to
activation of initiator Caspases 8 and 10, which can directly induce the downstream
executioner Caspase such as Caspase 3 and 7 to drive full commitment to apoptosis [28].
Moreover, Caspases 8 and Caspase 10 can activate Bid, which in turn activates Bak and
Bax to induce MOMP, which is the connecting link between the extrinsic and intrinsic
pathways [28] (Figure 2).
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Figure 2
The Programmed Cell Death Via Intrinsic and Extrinsic Pathways in Normal
Mammalian Cells

Note. Intrinsic and extrinsic pathways result in the activation of a family of protease
enzymes called Caspase proteins. The intrinsic pathway is promoted by cellular stresses
that modulate Bcl-2 family proteins and activate Bak and Bax. In the indirect activation,
upregulation of BH3-only proteins will act as inhibitors of anti-apoptotic proteins by
competing for their binding with Bax and Bak proteins, leading Bax and Bak to
oligomerize. In the direct activation, upregulation of BH3 activators proteins directly
activates Bax and Bak. This activation leads to mitochondrial outer membrane
8

permeabilization (MOMP), subsequently Cytochrome C and SMAC proteins release into
the cytosol, causing the downstream of Caspase activation that ends with apoptosis. The
extrinsic pathway is promoted by death receptors activation. This leads to activation of
initiator Caspases 8 and 10, which can regulate the downstream executioner Caspase such
as Caspase 3 and 7 to drive full commitment to apoptosis. Moreover, Caspases 8 and 10
can activate Bid, which in turn activates Bak and Bax to induce MOMP which establishes
the link between the extrinsic and intrinsic pathways.

The mitochondrial membrane engages Mcl-1 with other Bcl-2 family partners for
the initiation of apoptosis. The interaction between the family members determines the
outcome [26]. Mcl-1 has a diverse localization within human cells. It is primarily found
within the mitochondrial outer and inner membranes [29]. However, studies have
reported its localization in the nucleus and cytoplasm of polymorphonuclear leukocytes
(PMNs) [30]. How different localization affects the function and its stability is not
known.
The studies of Kozopas et al. first proved a high Mcl-1 expression in a
differentiating human myeloid leukemia ML-1 cell line [31]. Subsequently, it was shown
to be expressed in several different cells as well. The MM cells exhibit imbalances in
their anti-apoptotic proteins expression levels, especially Mcl-1 that leads to defects in
the mitochondrial intrinsic pathway [32, 33]. In order to prevent apoptosis and allow
continued cell growth, Mcl-1 forms a heterodimer protein-protein interaction with multidomain pro-apoptotic proteins Bax and Bak [34, 35]. Mcl-1 is known to be highly
9

expressed in MM cells and plays a pivotal role in MM initiation, progression, and
apoptosis resistance [32, 33]. Newly diagnosed cases of MM have continued to show
increasing Mcl-1 protein expression, which predicts a higher relapse and poor patient
survival rate [36]. Thus, Mcl-1 is an attractive therapeutic target for MM.
Regulation of Mcl-1 Protein
The interaction of myeloma cells to BM microenvironment (BMM) is the hall
mark of MM (Figure 3). Additionally, MM cells receive crucial signals from the BMM
that help them to evade apoptosis in order to maintain their long-term survival. The BM
stromal cells (BMSCs) regulate the anti-apoptotic Bcl-2 family proteins by secreting a
group of signaling cues. Mcl-1 is regulated through several extracellular signaling
molecules including interleukins (IL-3, IL-5, and IL-6) [37-39]; growth factors such as
vascular endothelial growth factor (VEGF), epidermal growth factor (EGF)[40, 41];
granulocyte macrophage colony stimulating factors (GM-CSF) [42]; and interferon alpha
(INF-α) [39]. Combined, these stimuli trigger and modulate multiple signaling pathways
including Janus kinase/signal transducer and activator of transcription (JAK/STAT), rat
sarcoma/mitogen-activated protein kinase (Ras/MAPK), MEK/extracellular signal-related
kinase (ERK) as well as phosphatidylinositol-3 kinase (PI3-K)/Akt (Figure 3).
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Figure 3
Bone Marrow Microenvironment (BMM) in MM

Note. BMM facilitates the long-term survival of MM. Stromal cells in BM regulate antiapoptotic proteins by secreting a variety of signaling molecules including IL-6 and IFN-α
that trigger JAK/STAT pathway, leading to the upregulation of Mcl-1, Bcl-xL,
and VEGF. VEGF promotes IL-6 induction in neighboring BMCs. Furthermore, IL-6
induces survival of MM cells via Ras/MAPK pathway, which modulates the expression
of Mcl-1 The tumor necrosis factor (TNF) family including BAFF and APRIL are other
stimuli from the BMM that induce expression of both Mcl-1 and Bcl-2 via tumor necrosis
factor receptor-associated factors (TRAFs) including BAFF-R, BCMA, and TACI. IGF-1
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is another stimulus that acts by downregulating Bim, leading to release Mcl-1. MM cases
have shown chromosomal amplification of 1q21 region, where the gene coding for Mcl-1
and IL-6R is located.

The cytokine IL-6 is the main survival factor for MM cells [43]. IL-6 triggers the
upregulation of Mcl-1, Bcl-xL, and VEGF via stimulation of the JAK/STAT-3 signaling
pathway [44, 45]. In turn, VEGF promotes IL-6 induction in neighboring BM cells
(BMCs) [45]. IL-6 also induces survival of MM cells via stimulating the Ras/MAPK
pathway, which engages in Mcl-1 overexpression [46]. Additionally, IFN-α induces Mcl1 in a STAT-3 dependent manner [39]. Furthermore, the tumor necrosis factor (TNF)
family, including B cell activating factor (BAFF) and a proliferation-inducing ligand
(APRIL), prevent apoptosis by inducing the expression of Mcl-1 and Bcl-2 [47]. Insulin
like growth factor 1 (IGF-1) affects the cell survival, by downregulating pro-apoptotic
protein Bim [48]. The imbalance between Bim and Mcl‐1 expression plays an important
role in MM cell survival [49]. The transcription factors such as B lymphocyte induced
maturation protein 1 (Blimp-1), X-box binding protein 1 (XBP-1), and interferon
regulatory factor 4 (IRF4) are critical for myeloma cells differentiation and development
[50]. The Blimp-1 downregulates the expression of pro-apoptotic protein Bim [51].
Mcl-1 and other anti-apoptotic proteins contain four Bcl-2 homology (BH)
domains (BH1-3 domains interact to form a hydrophobic cleft termed "BH3-binding
groove"), and a C-terminal tail of hydrophobic transmembrane domain (TM) that
permeates into the mitochondrial membrane [31]. Interestingly, compared to the other
12

anti-apoptotic proteins, Mcl-1 has several unique properties including binding site, size,
half-life, and localization. Mcl-1 has a shallow, relatively inflexible and more
electropositive binding site abundant in lysine and histidine residues [52]. Bcl-2 and BclxL proteins contain 233 amino acids, whereas Mcl-1 protein contains 350 amino acids.
This size difference is due to the presence of a large N-terminal domain of four PEST
sequences (amino acids sequence extensive in proline (P), glutamic acid (E), serine (S),
and threonine (T)) [31, 53], which can target Mcl-1 for degradation through the ubiquitinproteasome system (UPS) and renders it short half-life (usually less than three hours
depending on the cellular conditions) [29, 31, 54].
In MM, the Mcl-1 gene is the most important and selective of the survival genes
[55]. Gene coding of Mcl-1 is located on chromosome 1q21 region. Approximately 40%
of MM cases have shown chromosomal amplification of 1q21, hence increased Mcl-1
expression [56, 57]. Additionally, the gene coding of cytokine interleukin 6 receptor (IL6R) is located on the same chromosome region (1q21) [58]. The coding region of Mcl-1
contains three exons and two introns that undergoes alternative splicing to produce
mature RNA (mRNA) isoforms. The Mcl-1L (Mcl-1 long) splice variant joins the three
exons, has a full length of 350 amino acids and acts as an anti-apoptotic. On the other
hand, Mcl-1S (Mcl-1 short) joins only the first and the third exons without the central
exon, with the length of 271 amino acids, shows increased cytosolic localization and
lacks the BH1, BH2 and TM domains but has the BH3 domain which plays a critical proapoptotic role [59, 60]. Interestingly, Kim et al. (2009), found a new alternative splicing
variant detected in the mitochondrion termed Mcl-1ES (Mcl-1 extra short) with a shorter
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length of 197 amino acids due to an absence of PEST sequences [61]. Mcl-1ES forms an
interaction with Mcl-1L in order to induce apoptosis [61].
The post transcriptional regulation of Mcl-1 is complex and controlled by
multiple RNA binding proteins (RPBs) and microRNAs (miRNAs). For example, Mcl-1
has been shown to be downregulated in MM by miR-29b, miR-137, and miR-197 that
leads to apoptosis [62-64]. Additionally, at the post-translational level, the large Nterminal domain PEST allows for non-proteasomal degradation via cleavage [65],
proteasomal degradation via phosphorylation [53], and ubiquitination [66], which further
impact Mcl-1 expression, stability, localization, and function. Mcl-1 PEST undergoes
Caspase cleavage at two different sites, located at Asp127 that produce Mcl-1 1-127
associated with Mcl-1128-350. At Asp158 that produces Mcl-11-157 associated with Mcl-1158350

[65]. Interestingly, not all Mcl-1 cleavage fragments revoke anti-apoptotic function.

Mcl-1Δ127 fragment has anti-apoptotic function same as Mcl-1 and exists mainly in the
cytoplasm and sequester BH3-only or Bak in order to prevent apoptosis [67].
The Mcl-1 phosphorylation plays a critical role in controlling Mcl-1 function as
well. Mcl-1 phosphorylation occurs by several protein kinases including; c-Jun Nterminal kinase (JNK) [68], glycogen synthase kinase 3 (GSK-3) [69, 70], and
extracellular signal-regulated kinase (ERK-1) [71, 72]. The phosphorylated Mcl-1
proteins have been reported to result in different functions according to phosphorylation
sites [53, 73]. Furthermore, a reversible form of post-translational ubiquitination controls
several aspects of Mcl-1 including stability and proteasomal degradation and allows for
rapid response to environmental signals in order to change cell state from survival to
14

apoptosis. The Mcl-1 ubiquitin-proteasome system is mediated by five different E3
ubiquitin-ligases including Mcl-1 ubiquitin ligase E3 (Mule) [74], SCF beta-transducin
repeats containing protein (SCFβ-TrCP) [70], SCF F-box and WD repeat domain containing
7 (SCFFbw7) [75], anaphase-promoting complex/cyclosome (APC/CCdc20) [76], and
tripartite motif containing 17 (Trim17) [77]. Furthermore, the ubiquitin-proteasome
system contains an additional deubiquitinase called ubiquitin specific peptidase 9, Xlinked (USP9X) that removes poly-ubiquitin chains leading to stabilize Mcl-1 and
prevent apoptosis [78]. The degree of ubiquitination is also subject to variation based
upon the variable phosphorylation of residues of Mcl-1 [69, 70]. Our understanding of
Mcl-1 regulations has been greatly expanded by the findings that have developed over the
years and provide deep critical insights into exactly how Mcl-1 protein plays such a key
role in cellular apoptosis as well as how it can be modulated to provide new options of
potential therapeutic approach in MM and other Mcl-1 dependent cancers.
Development of Selective Mcl-1 Inhibitors
Studies have demonstrated that MM depends on Mcl-1 proteins for survival,
prognosis, and chemo resistance. Thus, inhibition of Mcl-1 offers an attractive target and
a promising strategy for myeloma treatment. Nonetheless, the targeting of Mcl-1 has
been challenging because of its complex regulation. So far, two approaches have been
adopted to inhibit Mcl-1, one is direct inhibition and the second is indirect targeting.
Indirect targeting is a less selective method that inhibits other anti-apoptotic proteins,
may have more serious side effects. Whereas direct Mcl-1 inhibitors target the
hydrophobic cleft BH3-binding groove of BH3-only proteins interactions domain.
15

Therefore, these inhibitors are very specific to Mcl-1. Here we will review BH3-mimetic
inhibitors that selectively bind Mcl-1. The structures of these inhibitors are shown in
Figure 4. The current status of development of these agents are summarized in Table 2.
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Figure 4
Chemical Structures of Selective Mcl-1 Inhibitors

A-1210477

Maritoclax

MIM1

UMI-77

S63845

17

S64315 or MIK666

AMG-176

AZD5991

VU661013

Note. The most prominent Mcl-1 inhibitors including A-1210477, Maritoclax, MIM1, UMI-77, S63845, S64315/MIK666,
AMG-176, AZD5991, and VU661013.

Table 2
Direct Mcl-1 Inhibitors BH3 Mimetic and Semi BH3 Mimetic Agents
Mcl-1 Inhibitor

Company

Affinity

Clinical Trial Status

A-1210477

Abbive

Ki = 0.45 nM

Preclinical

Maritoclax

Hong-Gang Wang's group at

IC50 10 μM

Preclinical

Only at very high

Failed in vivo

Pennsylvania State University
MIM1

Cohen and co-workers

concentration
UMI-77

Zaneta Nikolovska-Coleska's

Ki = 490 nM

Preclinical

18

group at University of
Michigan
S63845

Servier & Vernalis

Kd = 0.19 nM

Preclinical

S64315/MIK666

Servier & Vernalis and

Undisclosed

Phase I by Novartis, in R/R lymphoma or R/R

Novartis

MM patients (NCT02992483).
Phase I by Servier, in AML and MDS patients
(NCT02979366).
Phase I by Servier as a combination of
S64315/MIK666 plus Venetoclax in AML
patients (NCT03672695).

Mcl-1 Inhibitor

Company

Affinity

Clinical Trial Status

AMG-176

Amgen

Ki = 0.06 nM

Phase I in R/R MM and R/R AML patients
(NCT02675452).
Phase I as a combination of AMG-176 plus
Venetoclax in different R/R hematologic
malignancies including AML, NHL, and
DLBCL (NCT03797261).

AMG-397

Amgen

Undisclosed

Phase I clinical trial is evaluating the safety,
tolerability, pharmacokinetics, and efficacy of
AMG 397 in MM, AML, DLBCL, and NHL
patients (NCT03465540).
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AZD5991

AstraZeneca

Ki = 0.2 nM

Phase I as a monotherapy in different R/R
hematologic malignancies including NHL,
ALL, RS, SLL, T-cell lymphoma, CTCL,
CLL, AML/ MDS, and MM patients
(NCT03218683).
Phase II is sequential, dose-escalation study of
combination AZD5991 plus Venetoclax in R/R
AML/MDS patients (NCT03218683).

VU661013

Stephen Fesik’s group at
Vanderbilt University

Ki = 0.097 nM

Have partnership with Boehringer Ingelheim
Company for clinical trials but no plan

Mcl-1 Inhibitor

Company

Affinity

Clinical Trial Status
disclosed yet. (https://www.boehringeringelheim.us/press-release/boehringeringelheim-and-vanderbilt-university-expandpartnership-develop-novel)
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Indole-2-Carboxylic Acids Analog (A-1210477)
This was developed by AbbVie in 2008. A-1210477 induces intrinsic apoptosis
pathway by selectively inhibiting Mcl-1 with high binding affinity (Ki = 0.454 nM) [79].
Upon binding, BH3 mimetic A-1210477 results in an accumulation of Mcl-1 protein by
preventing its degradation. A-1210477 disrupts the Mcl-1:Bim and Mcl-1:Noxa
complexes in order to induce Bax/Bak- dependent MOMP, leading to Cytochrome C
release and Caspase activation [79]. The treatment of A-1210477 decreased the
association of Mcl-1: Bak complex within an hour, however the complex was totally
disrupted after three hours of treatment [80]. Interestingly, the studies of Mallick et al.
(2019) showed that A-1210477 induces rapid apoptosis within 0.5–1 hour of treatment,
without inducing Noxa [81]. A-1210477 as a monotherapy or in a combination with
Navitoclax resulted in the death of different cell lines including MM, melanoma, and
non-small cell lung cancer cell lines that were found to be Mcl-1 dependent by BH3
profiling or siRNA rescue experiments [79, 82]. This finding was reinforced by the
efficacy of A-1210477 as a combination with Venetoclax against acute myeloid leukemia
(AML) [83]. A-1210477 inhibited triple negative breast cancer cell line growth activity in
vitro which is also considered a Mcl-1 dependent cells type [84]. However, a reference
showed A-1210477 induced apoptosis in Bcl-2 dependent cells at higher concentration
when compared with Mcl-1 inhibition concentration [85]. Unfortunately, no in vivo
activity was associated with A-1210477, even with the most sensitive cell lines. This was
attributed to cell penetration issues and reduced bioavailability due to the high levels of
serum protein binding.
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Marinopyrrole A (Maritoclax)
This natural agent was first discovered by Hong-Gang Wang's group at
Pennsylvania State University in 2012 [86]. The BH3 mimetic drug Maritoclax induces
degradation of Mcl-1 proteins and disrupts Mcl-1: Bim complex . Maritoclax effectively
binds the site of the BH3-only proteins p4 binding site and leads to apoptosis. Further, it
has been reported that this natural agent is effective against Mcl-1 overexpressing cancer
cells [86]. Blocking BH3 binding site is related with increased amounts of Mcl-1 protein,
followed by its ubiquitination and degradation by the E3 ligase (ubiquitin ligase) [87].
Moreover, the treatment of Maritoclax did not result in Noxa upregulation [86]. We
found that Maritoclax potentiates the apoptotic response of ABT-737 in human
melanoma cells [88].
Mcl-1 Inhibitor Molecule 1 (MIM1)
Developed in 2012 by Cohen and co-workers, polyphenol compound MIM1 acts
as a semi BH3 mimetic which induces Noxa [89]. MIM1 seems very similar to BH3
mimetic Mcl-1 inhibitors [81]. This Mcl-1 inhibitor exhibited an ability to induce
apoptosis in Mcl-1 dependent cells through upregulation of proapoptotic protein Noxa,
which selectively inhibits Mcl-1 with high affinity binding [25, 26, 81]. Also, induction
of Noxa dissociates Mcl-1:Bim association complex. Unfortunately, MIM1 was only able
to induce Bak dependent apoptosis at high concentrations (more than 10 μM). MIM1
failed to induce apoptosis in anti-apoptotic proteins dependent cell lines [90].
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UMI-77
Developed in 2013 by Zaneta Nikolovska-Coleska's group at University of
Michigan, naphthol derivative UMI-77 is another semi BH3 mimetic Mcl-1 inhibitor with
a high binding affinity (Ki = 490 nM) [91, 92]. In order to induce apoptosis, UMI-77 was
found to upregulate pro-apoptotic protein Noxa thereby selectively inhibiting Mcl-1 [81].
UMI-77 and Noxa competing for Mcl-1 binding with Bax and Bak proteins ultimately
disrupt the Mcl-1: Bak and Mcl-1: Bak complexes, which results in Cytochrome
C release and Caspase 3 activation [92]. The in vitro and in vivo preclinical studies
demonstrated that UMI-77 potently inhibits tumor growth and induces apoptosis in MM
cells [91], and pancreatic cancer cells lines [92], both of which rely on the Mcl-1 protein
as a survival factor [93-95]. In addition to pancreatic cancer cell line BxPC-3 xenograft
mouse model and MM animal xenografts, UMI-77 significantly delayed growth activity
in breast cancer cell line MDA-MB-468 xenograft mouse model as well [84].
S63845
Developed in 2015 by a Servier and Vernalis partnership, atropisomers
thienopyrimidine scaffold molecule S63845 is a selective BH3 mimetic Mcl-1 inhibitor
that can activates the Bax/Bak dependent mitochondrial apoptotic pathway [96]. S63845
is a selective and potent BH3 mimetic. It binds with high affinity to the BH3-binding
groove of Mcl-1 (Kd = 0.19 nM) without any detectable binding to Bcl-2 or Bcl-xL
proteins. S63845 showed effective anti-cancer activity in its in vitro and in vivo
preclinical studies [96]. The IV infusion of S63845 once daily for five consecutive days
resulted in 100% tumor regression in MM subcutaneous tumor models and lymphoma
23

disseminated mouse model Eμ-Myc [96, 97]. The same tumor regression was related to
AML as well [96]. This inhibitor had a therapeutic effect without significant weight loss
apparent side effects in normal mice tissues [96]. Along with A-1210477 and UMI-77,
S63845 also inhibited the growth activity of TN breast cancer cell line [84].
After S63845 proved its eligibility as a selective Mcl-1 antagonist, impressive
studies have continued coming up. Recently in 2019, S63845 showed activity both in
vitro and in vivo by killing human T cell acute lymphoblastic leukemia cells (T-ALL)
[98]. It was even more potent in inducing apoptosis as a combination therapy with
Venetoclax without any appreciable toxicity [98]. In 2020, in vitro, ex vivo, and in vivo
preclinical evaluations investigated the combination of S63845 plus Venetoclax. In vitro
study tested the sensitivities of five MM cell lines to the drug while the in vivo study used
an aggressive disseminated model of MM. The combined finding came clearly with
increasing apoptotic cell death, reduced cell survival as well as delayed tumor growth in
vivo [99]. Furthermore, S63845 was evaluated in a triple combination with Venetoclax
plus dexamethasone. Clearly, in vitro and in vivo studies showed that dexamethasone
increased the effectiveness of both S63845 and Venetoclax. Furthermore, in vitro studies
illustrated that triple therapy is a stronger synergism than the S63845 plus Venetoclax in
resistant MM cell line (MM.1S) [99]. In addition, the combination of S63845 and
Venetoclax, enhanced the Venetoclax sensitivity and overcome resistance to Venetoclax
in human myeloma cell lines (HMCLs) [100].
Servier & Vernalis and Novartis have created another S-derivative called S64315
or MIK666. S64315/MIK666 is in clinical trial as a single agent in R/R lymphoma or R/R
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MM (NCT02992483). Furthermore, this molecule is being tested in AML and
myelodysplastic syndrome (MDS) patients (NCT02979366). Another clinical trial is
undergoing by Servier & Vernalis in a combination with Venetoclax in AML patients
(NCT03672695).
AMG-176
Developed in 2016 by Amgen, chirality macrocyclic acylsulfonamide
(spiromacrocyclic) AMG-176 is an orally selective Mcl-1 inhibitor with high binding
affinity (Ki = 0.06 nM), induces rapid apoptosis in different hematologic malignancies.
The treatment of AMG-176 disrupts the interactions of the Mcl-1: Bak complex [101]
[102]. Preclinical studies have demonstrated that AMG-176 is non-toxic and efficacious
in both MM subcutaneous xenograft models and disseminated models, inhibiting 100%
tumor growth [101]. In preclinical studies, AMG-176 has been shown to eradicate CLL
cells as a single agent or in a combination with a low dose of Venetoclax [103].
Interestingly, AMG-176 was the first selective Mcl-1 inhibitor to be studied in humans.
Currently, AMG-176 is in phase I clinical trials via IV administrations in patients with
R/R MM and patients with R/R AML (NCT02675452). AMG-176 monotherapy has
potent anti-myeloma and unique hematologic activity resulting in marked survival
improvement. Furthermore, phase I clinical trials have also evaluated AMG-176 as a
combination therapy with Venetoclax which presents as an interesting therapy for
different R/R hematologic malignancies including AML, diffuse large B cell lymphoma
(DLBCL), and Non-Hodgkin's lymphoma (NHL) (NCT03797261). Furthermore, as a
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combination with MEK inhibitor (Trametinib), AMG-176 increased the tumor regression
effect in murine models of solid tumor cell lines [104].
Amgen has developed another potent and selective analog AM-8621, nonetheless,
this molecule has poor oral bioavailability and a short half-life [101]. Interestingly, MM
cells showed sensitivity to AM-8621 as a monotherapy and as a combination therapy
with dexamethasone [101]. Caenepeel et al. (2019) investigated the activities of AMG
176 and AM-8621 in combination with Cytarabine, Doxorubicin, and Decitabine in a
preclinical model of AML [105]. The other analog AMG-397 is evaluated orally in the
clinic. A phase I clinical trial evaluating its safety, tolerability, pharmacokinetics, and
efficacy in MM, AML, DLBCL, and NHL patients by administrating AMG-397 in a
weekly cycle consisting of two consecutive days of one oral dose followed by five days
off at a weekly interval (NCT03465540).
AZD5991
Developed in 2017 by AstraZeneca, indole-2-carboxylic acids analog AZD5991,
is a potent and selective macrocyclic Mcl-1 inhibitor that rapidly activates Caspase
proteins, which leads to apoptosis in MM cell lines (GI50 = 10 nM) [106, 107]. AZD5991
is a BH3 mimetic with high binding affinity (Ki = 0.2 nM) disrupts the Mcl-1: Bak
complex [106, 107]. Most notably, in a number of MM and AML mouse and rat
xenograft models, AZD5991 exhibits a potent activity with the preclinical in vivo studies
showing 100% tumor regression after a single IV dose in both monotherapy and in
combination with Venetoclax or Bortezomib [107]. The preclinical efficacy of AZD5991
is emphasized by the apoptosis and survival improvements in MM models resistant to
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Venetoclax [106]. The remarkable in vitro and in vivo anti-tumor activities of AZD5991
in both MM and AML models support its consideration as a strong clinical candidate in
different Mcl-1 dependent hematologic malignancies. The number of clinical trials are
ongoing with AZD5991 as a single agent or in combinations. For example, phase 1 as a
monotherapy dose escalation study in several R/R hematologic malignancies including
NHL, ALL, Richter syndrome (RS), small lymphocytic lymphoma (SLL), T-cell
lymphoma and cutaneous T-cell lymphoma (CTCL) (NCT03218683); phase 1 as a
monotherapy in expansion groups of R/R CLL, AML/ MDS, and MM patients; and Phase
2 sequential, dose-escalation study in combination with Venetoclax in R/R AML/MDS
patients (NCT03218683).
VU661013
Developed in 2017 by Stephen Fesik’s group at Vanderbilt University, indole-2carboxylic acids analog VU661013 is a potent and selective BH3 mimetic Mcl-1 inhibitor
with a high binding affinity (Ki=0.097 nM) [108]. VU661013 destabilizes the Mcl-1:
Bim complex in order to initiate MOMP [109]. VU661013 proved potency in Mcl-1
inhibition in both in vitro and in vivo studies through its induction of apoptosis in a
variety of Mcl-1 dependent tumors. Furthermore, it demonstrated efficacy in combination
with Venetoclax in Venetoclax resistant cells, patient derived xenografts, and murine
models of AML [109]. Further modifications of this molecule are being made to improve
the efficacy and bioavailability. Another analog has been made (compound 42), which is
bound to Mcl-1 with picomolar affinity (Ki= 70-300 pM) in order to displace Bim [110].
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Compound 42 showed in vivo growth inhibition in xenograft models of MM and AML
[110].
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Chapter 2
Methods and Materials
Antibodies and Compounds
Antibodies were obtained from the following sources: mouse anti-Bcl-2 (Cell
Signaling, 3498); rabbit anti-Mcl-1 (Cell Signaling, 94296); rabbit anti-Bcl-xL (Cell
Signaling 2762); rabbit polyclonal anti-caspase-3 (Cell signaling, 9662); rabbit
polyclonal cleaved caspase-3 (Cell Signaling, 9664); rabbit polyclonal anti-PARP (Cell
Signaling, 9532); rabbit anti-GAPDH (Sigma-Aldrich, G9545). Thiazolyl Blue
Tetrazolium Bromide (MTT) was purchased from Sigma-Aldrich.
Cell Culture
All MM cell lines (U266, MM.1S, MM.1R, and RPMI 8226) were obtained from
American Type Culture Collection (ATCC) and maintained per the manufacturer’s
recommendations in complete medium with 1% HyClone TM antibiotic/antimycotic
solution 100X (10,000 U/mL Penicillin G, 10,000 μg/mL Streptomycin, 25 μg/mL
Amphotericin B) at 37°C and 5% Carbon dioxide (CO 2). MM.1S, MM.1R, and RPMI
8226 cell lines maintained in RPMI 1640 medium 10% fetal bovine serum (FBS). While
U266 cells were maintained in RPMI 1640 medium supplemented with 15% FBS.
The cell lines were stored in liquid nitrogen. Then every cell line was allowed to
thaw at 25°C room temperature before being diluted in a centrifuge tube with 5 mL of
media and centrifuged for 5 minutes at 900 RPM. Next, the supernatant fluid was
discarded and the pellet was resuspended in an appropriate volume of fresh media by
slowly pipetting up and down. Lastly, the mixture was transferred to a T25 cell culture
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flask and placed in the incubator. The cells were allowed to grow and were screened
under the microscope; afterward, the media and flask were exchanged accordingly
(Figure 5).

Figure 5
The Placement of Flasks in CO2 Incubator

Cell Viability Assay
The effect on cell viability of KS18 was determined by MTT Assay. First, 5000
cells of each cell line were incubated with (0.1-25 µM) concentrations of KS18 in
triplicates using a 96-well plate in a final volume of 200 µL for 96 hours at 37°C.
Afterward, 20 µL of MTT dye (5 mg/mL in PBS) was added to each well and incubated
for 3 hours at 37 °C. After 3 hours of incubation, the 96-well plate was centrifuged for 7
minutes at 1000 rpm, and then the supernatant fluid was removed and 50 µL of DMSO
was added to each well to dissolve the resulting formazan crystals (Figure 6). The optical
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density of the resulting solution was measured at delta value (570-630 nm) using a 96well multi-mode microplate reader (BioTek Technologies, Synergy H1; Winooski, VT,
USA). The optical density is directly correlated to the number of viable cells remaining in
the solution. The percentage of cell viability was calculated by comparing the
concentration of formazan crystals formed in each well with the negative control, which
has no molecules add.

Figure 6
MTT Assay Mechanism

Western Blot Analysis
The effect of KS18 on Mcl-1 and associated apoptotic pathways was determined
by Western Blot. Whole-cell extracts were prepared by subjecting nontreated (negative
control) and treated cells to 50 µL of lysis buffer (643 µL RIPA buffer supplemented
with 7 µL of 100 X protease/phosphatase inhibitor) in microcentrifuge tubes. After one
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hour, lysates were vortexed vigorously three times then spun down at 13,000 rpm for 10
minutes to remove insoluble material. The supernatant was collected into a new
microcentrifuge tube and kept at -80°C. BCA protein estimation was employed using to
the extracts and the BCA Protein assay kit (Pierce TM BCA Protein Assay Kit; Thermo
scientific. Rockford, IL, USA). The protein of each sample was diluted with the proper
amount of distilled water, NuPAGE LDS Sample Buffer dye (4X) (Thermo scientific,
89901; Rockford, IL, USA), and DTT (10X), so that 30 ug of protein was loaded per well
into a 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDSPAGE) gel.
The gel was subjected to electrophoresis with added SDS running buffer to the center of
the chamber at 110 V at room temperature until the dye reached about half a centimeter
above the three grooves of the chamber. After electrophoresis, the proteins were electrotransferred to PVDF membranes at 34 V for 90 minutes with added transfer buffer to the
center of the chamber and ice and cold water to the back part of the chamber. The
membrane was blocked with 5% nonfat dry milk in 1X PBST (phosphate-buffered saline)
(VWR, 20A0756203; Ohio, USA) with 0.05% Tween-20 (Sigma Chemical Co., St.
Louis, MO, USA) for 35-45 minutes, subsequently washed with PBST, then blotted with
the relevant antibodies (5 µL 1°Ab: 5 mL 5% nonfat dry milk in PBST) overnight in the
cold room with shaking. After that, the blot was washed with PBST three times for 5
minutes each, then exposed to horseradish peroxidase (HRP)–conjugated secondary
antibodies (1 µL 2°Ab: 5 mL 5% nonfat dry milk in PBST) for two hours at room
temperature with shaking. Finally, the blot had another three washes with PBST for 5
minutes each, followed by exposure to an enhanced chemiluminescent substrate for
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detection of HRP (PierceTM ECL Western; Thermo scientific. Rockford, IL, USA). The
bands obtained were quantitated using the Imaging system (BIO-RAD, ChemiDoc TM MP;
Hercules, CA, USA). To save time and precious samples, sequential detections of
different proteins were performed on the same membrane using Gentle ReView™
Stripping Buffer (VWR, 19G0856497; Ohio, USA). All critical blots experiments were
repeated at least two to three times.
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Chapter 3
Results and Discussion
KS18 and Mcl-1 Anti-Apoptotic Protein
KS18 is a potent pyoluteorin derivative that inhibits Mcl-1 protein selectively in
order to induce Mcl-1 dependent apoptosis (Figure 7) [111]. Pyoluteorin is a natural
antibiotic, first isolated in the 1950s from cultures of Pseudomonas aeruginosa strains
[112]. Pyoluteorin is a small molecule produced by fluorescent Pseudomonas [113].
Remarkably, according to NMR, pyoluteorin derivatives were shown to induce a
conformational change in Mcl-1 [111]. Pyoluteorin derivatives are now being studied as a
selective Mcl-1 inhibitor in order to target Mcl-1 dependent cancers [111].

Figure 7
Chemical Structures of Pyoluteorin and KS18

Pyoluteorin

KS18

This project was conducted to establish the hypothesis that the small molecule
KS18 induces apoptosis in MM by targeting Mcl-1 selectively. The goal of this project
aimed to evaluate KS18 selectivity towards Mcl-1 and potency in inducing Mcl-1
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dependent apoptosis in MM. The research model of in vitro studies was four different
MM cell lines.
KS18 Molecule Reduces Cell Viability of MM
We further demonstrated the effects of KS18, a novel selective Mcl-1 inhibitor,
on the cell viability of MM cells by using MTT assay. Figure 9 illustrates that Mcl-1
inhibition by KS18 reduced the cell viability of MM cells. Thereby, KS18 induced
apoptosis in MM cells by inhibiting Mcl-1.
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Figure 8
Effect of KS18 on Cell Viability of MM Cells

Note. MM cells were treated with increasing concentrations of KS18 (0.1–25 µM) for 96
hrs.

Anti-Apoptotic Proteins Expression in MM Cells
We first investigated the expression levels of anti-apoptotic Bcl-2 family proteins
(Bcl-2, Bcl-xL, and Mcl-1) in MM cells including MM.1S, MM.1R, U266, and
RPMI8226. Remarkably, U266 cells have shown the highest expression of Mcl-1 protein
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whereas the expression of Bcl-2 was found to be highest in RPMI8226 cells (Figure 8).
These findings confirmed that Mcl-1 plays a critical role in MM cells. Our results
indicate that U266 cells have the highest expression of Mcl-1. Accordingly, the U266 cell
line has been selected for further investigation.

Figure 9
Anti-Apoptotic Proteins Expression in MM Cell Lines

KS18 Selectively Inhibits Mcl-1 Expression in U266 Cells
Mcl-1 is known to be highly expressed in MM cells and plays a crucial role in
MM survival. Since KS18 is a novel selective Mcl-1 inhibitor, we investigated the effects
of KS18 on Mcl-1 expression in U266 cells. As expected, KS18 provided sufficient
inhibition of Mcl-1 protein, whereas no effect on Bcl-2 and Bcl-xL expression. Figure 10
A illustrated that dose-dependent of KS18 inhibits Mcl-1 selectively. Furthermore, 5µM
concentration of KS18 showed a significant inhibition of Mcl-1. Thus, 5µM
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concentration was selected for time-dependent experiment. Figure 10 B illustrated that
time-dependent of KS18 (5µM) inhibits Mcl-1 selectively.

Figure 8
Down-Regulation of Mcl-1 by KS18 in U266 Cells

A)

B)
Note. A, Dose-dependent effect of KS18 on Mcl-1 and other anti-apoptotic proteins in
U266 cells. B, Time-dependent effect of KS18 (5µM) on Mcl-1 and other anti-apoptotic
proteins in U266 cells.
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KS18 Induces Apoptosis in Caspase-Dependent Manner
Since our results have proven Mcl-1 inhibition by KS18, we were interested in
expanding our experiments to investigate the effect of KS18 on associated apoptotic
pathway in MM cells. Remarkably, our results confirmed that KS18 induces caspase-3
activation in U266, simultaneously inducing caspase-3 and PARP cleavage dose and
time-dependently (Figure 11 A & B).
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Figure 9
Inhibition of Mcl-1 Induces Apoptosis in U266 Cells

A)

B)

Note. A, Dose-dependent effect of KS18 on apoptotic proteins in U266 cells. B, Timedependent effect of KS18 (5µM) on apoptotic proteins in U266 cells.
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Chapter 4
Conclusion and Future Direction
MM evades apoptosis by exhibiting an imbalance in anti-apoptotic proteins
expression, especially Mcl-1, leading to a defective intrinsic pathway [32, 33]. Mcl-1
protein is essential for the survival and uncontrolled growth of malignant plasma cells.
Therefore, Mcl-1 overexpression in MM plays a crucial role in tumor initiation,
progression, and relapse [36]. Small molecule targeting of Mcl-1 protein forms an
attractive strategy for MM therapy. Thus, the recent research efforts have been focused
on discovering a selective Mcl-1 inhibitor with the ambition of developing a promising
new treatment for MM.
The anti-apoptotic protein Mcl-1 is critical in the survival and drug resistance of
several malignancies including MM [36] [93, 117-122]. Mcl-1 overexpression is one of
the main factors in the development of the resistance to current selective Bcl-2/Bcl-xL
inhibitors [114, 115]. ABT-737, a Bcl-2 and Bcl-xL inhibitor, is highly potent against
Bcl-2 dependent cancers but has no efficacy towards Mcl-1 dependent cancers [116].
KS18 is a pyoluteorin analogue that behaves as a selective Mcl-1 inhibitor with
high cytotoxic potency in MM. This project demonstrated that KS18 induces apoptosis in
MM cells by inhibiting Mcl-1 protein specifically (Figure 10 A & B). Furthermore, our
results suggest activation of caspase-dependent apoptosis, where we confirmed caspase-3
and PARP cleavage after dose and time-dependent Mcl-1 down regulation (Figure 11 A
& B).
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Taken together, our results support that Mcl-1 selective inhibitors are associated
with achieving an extreme therapeutic efficacy and may also overcome drug resistance of
Bcl-2/Bcl-xL inhibitors in MM. Combinations strategies are shown to be especially
valuable if the combination consists of a selective Mcl-1 inhibitor plus a molecule that
inhibits other anti-apoptotic proteins including Bcl-2 and Bcl-xL, or a molecule that
induces pro-apoptotic proteins expression.
The last decade or so has seen tremendous development in novel molecules and
various Mcl-1 inhibitors have been developed. These new inhibitors may help in
overcoming drug resistance and improve the treatment of MM and other hematological
malignancies where Mcl-1 is an important survival factor. Interestingly, KS18 may form
a very potent molecule in managing malignancy of MM and enhances the efficacy of
MM treatment in order to overcome resistance. Therefore, our results suggest that KS18
by targeting Mcl-1 may represent a new viable treatment for MM. The future studies
uncover the mechanism of action of KS18 and provide the foundation for in vivo
assessment of this novel small molecule. The in vivo studies utilizing MM mouse model
are needed to understand how KS18 downregulates Mcl-1 protein and whether this
molecule potentiates the response of approved therapeutic agents in MM. Based on this
information, the small molecule targeting of Mcl-1 represents one of the most promising
approaches for MM treatment. This places priority on the rational design of novel
molecules that bind extremely tightly and selectively to Mcl-1 for the better outcome of
the treatment.
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